Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients

被引:6
|
作者
Grucz, Traci M. [1 ]
Kruer, Rachel M. [2 ]
Bernice, Fidelia [1 ]
Lipsett, Pamela A. [3 ,4 ]
Dorman, Todd [4 ]
Sugrue, David [1 ]
Jarrell, Andrew S. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Pharm, 600 North Wolfe St,Carnegie 180, Baltimore, MD 21287 USA
[2] Indiana Univ Hlth, Dept Pharm, Indianapolis, IN USA
[3] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA
关键词
aminoglycosides; critical illness; pharmacokinetics; therapeutic drug monitoring; PEAK CONCENTRATION; GENTAMICIN; PHARMACOKINETICS; AMIKACIN;
D O I
10.1089/sur.2020.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: At a tertiary referral and Level I trauma center, current institutional guidelines suggest initial aminoglycoside doses of gentamicin or tobramycin 4 mg/kg and amikacin 16 mg/kg for patients admitted to surgical intensive care units (SICUs) with suspected gram-negative infection. The objective of this study was to evaluate initial aminoglycoside dosing and peak serum drug concentrations in critically ill surgery patients to characterize the aminoglycoside volume of distribution (V-d) and determine an optimal standardized dosing strategy. Methods: This retrospective, observational, single-center study included adult SICU patients who received an aminoglycoside for additional gram-negative coverage. Descriptive statistics were used to evaluate the patient population, aminoglycoside dosing, and V-d. Multivariable linear regression was applied to determine variables associated with greater aminoglycoside V-d. The mortality rate was compared in patients who achieved adequate initial peak concentrations versus those who did not. Results: One hundred seventeen patients received an aminoglycoside in the SICUs, of whom 58 had an appropriately timed peak concentration measurement. The mean Acute Physiology, Age, and Chronic Health Evaluation (APACHE) II score was 27.8 +/- 8.9. The V-d in patients receiving gentamicin, tobramycin, and amikacin was 0.49 +/- 0.10, 0.41 +/- 0.09, and 0.53 +/- 0.13 L/kg, respectively. Together, the mean aminoglycoside V-d was 0.50 +/- 0.12 L/kg. Gentamicin or tobramycin 5 mg/kg achieved goal peak concentrations in 24 patients (63.2%), and amikacin 20 mg/kg achieved the desired concentrations in nine patients (50.0%). Net fluid status, Body Mass Index, and vasopressor use were not predictive of V-d. There was no difference in the in-hospital mortality rate in patients who achieved adequate peak concentrations versus those who did not (26.8% versus 26.7%; p = 0.99). Conclusion: High aminoglycoside doses are needed in critically ill surgery patients to achieve adequate initial peak concentrations because of the high V-d. Goal peak concentrations were optimized at doses of gentamicin or tobramycin 5 mg/kg, and amikacin 20 mg/kg.
引用
收藏
页码:859 / 864
页数:6
相关论文
共 50 条
  • [21] Optimizing dosing of antibiotics in critically ill patients
    Parker, Suzanne L.
    Sime, Fekade B.
    Roberts, Jason A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2015, 28 (06) : 497 - 504
  • [22] Initial dosing of vancomycin in critically ill patients
    Kees, Martin G.
    Voegeler, Stephan
    Hilpert, Justus W.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 38 (01) : 91 - 92
  • [23] PREDICTED AND MEASURED AMINOGLYCOSIDE PHARMACOKINETIC PARAMETERS IN CRITICALLY ILL PATIENTS
    HASSAN, E
    OBER, J
    CRITICAL CARE MEDICINE, 1986, 14 (04) : 394 - 394
  • [24] AMINOGLYCOSIDE NEPHROTOXICITY - COMPARATIVE-ASSESSMENT IN CRITICALLY ILL PATIENTS
    PLAUT, ME
    SCHENTAG, JJ
    JUSKO, WJ
    JOURNAL OF MEDICINE, 1979, 10 (04) : 257 - 266
  • [25] CONTINUOUS ARTERIOVENOUS HEMOFILTRATION OF AMINOGLYCOSIDE ANTIBIOTICS IN CRITICALLY ILL PATIENTS
    ZAROWITZ, BJ
    ANANDAN, JV
    DUMLER, F
    JAYASHANKAR, J
    LEVIN, N
    JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (08): : 686 - 689
  • [26] PREDICTED AND MEASURED AMINOGLYCOSIDE PHARMACOKINETIC PARAMETERS IN CRITICALLY ILL PATIENTS
    HASSAN, E
    OBER, JD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (11) : 1855 - 1858
  • [27] AMINOGLYCOSIDE PHARMACOKINETICS IN OBESE CRITICALLY ILL PATIENTS: A RETROSPECTIVE STUDY
    Nardone, Alexa
    Droege, Chris
    Keegan, Shaun
    Ernst, Neil
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 449 - 449
  • [28] Dosing Guidance for Intravenous Colistin in Critically Ill Patients
    Nation, Roger L.
    Garonzik, Samira M.
    Thamlikitkul, Visanu
    Giamarellos-Bourboulis, Evangelos J.
    Forrest, Alan
    Paterson, David L.
    Li, Jian
    Silveira, Fernanda P.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (05) : 565 - 571
  • [29] Oseltamivir Dosing in Critically Ill Patients With Severe Influenza
    Flannery, Alexander H.
    Bastin, Melissa L. Thompson
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (08) : 1011 - 1018
  • [30] Vancomycin Dosing for Pneumonia in Critically Ill Trauma Patients
    Patanwala, Asad E.
    Norris, Christopher J.
    Nix, David E.
    Kopp, Brian J.
    Erstad, Brian L.
    JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2009, 67 (04): : 802 - 804